425: BD Files SEC Communication on Proposed Spin-Off and Merger of Biosciences Unit with Waters Corporation

Becton, Dickinson and Company has filed a Rule 425 communication with the SEC regarding the proposed business combination of its biosciences and diagnostic solutions business, Augusta SpinCo Corporation, with Waters Corporation, outlining forward-looking statements and associated risks.

Summary

• Becton, Dickinson and Company (BD) has filed a Rule 425 communication with the U.S. Securities and Exchange Commission (SEC) concerning a proposed business combination.
• The transaction involves Waters Corporation (Waters) and Augusta SpinCo Corporation (SpinCo), which is BD's biosciences and diagnostic solutions business.
• The communication includes forward-looking statements regarding the expected timing, structure, completion, benefits, tax consequences, and financing of the proposed transaction.
• It highlights that actual results could differ materially from current expectations due to a number of risks and uncertainties, many of which are beyond Waters' and BD's control.
• The parties intend to file further relevant materials with the SEC, including a registration statement on Form S-4 by Waters and a registration statement on Form 10 by SpinCo, which will include proxy statements and information statements for investors.

Sentiment

Score: 6

Explanation: The document announces a significant business combination, which is generally a positive strategic move. However, its primary purpose is to disclose extensive risks and uncertainties associated with forward-looking statements, which tempers the overall sentiment. It is informative and legally compliant, presenting a balanced view of potential outcomes.

Positives

• The proposed transaction is expected to yield anticipated benefits, including the amount and timing of synergies.

Negatives

• Uncertainty exists regarding the expected financial performance of the combined company following completion of the proposed transaction.
• There is a risk of unexpected costs, charges, or expenses resulting from the proposed transaction.
• Potential for greater than expected difficulty in separating SpinCo's business from BD's other operations is identified as a risk.

Risks

• One or more closing conditions to the transaction, including certain regulatory approvals, may not be satisfied or waived on a timely basis or otherwise.
• A governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the proposed transaction, or may require conditions, limitations, or restrictions.
• The required approval by the stockholders of Waters may not be obtained.
• The proposed transaction may not be completed on the terms or in the time frame expected by Waters, BD, and SpinCo, or at all.
• Failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the proposed transaction or integrating the businesses of Waters and SpinCo, on the expected timeframe or at all.
• The ability of the combined company to implement its business strategy may be challenged.
• Difficulties and delays in the combined company achieving revenue and cost synergies are possible.
• The combined company may face an inability to retain and hire key personnel.
• The occurrence of any event that could give rise to termination of the proposed transaction is a risk.
• Stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification, and liability.
• Evolving legal, regulatory, and tax regimes could impact the transaction.
• Changes in general economic and/or industry-specific conditions or any volatility resulting from the imposition of and changing policies around tariffs are risks.
• Actions by third parties, including government agencies, could affect the transaction.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• There is a risk of greater than expected difficulty in separating the business of SpinCo from the other businesses of BD.
• Disruption of management time from ongoing business operations due to the pendency of the proposed transaction is a concern.
• Other effects of the pendency of the proposed transaction on the relationship of any of the parties to the transaction with their employees, customers, suppliers, or other counterparties are potential risks.

Future Outlook

The document outlines forward-looking statements regarding the proposed business combination between Waters Corporation and Augusta SpinCo Corporation, including expectations for the transaction's timing, structure, completion, anticipated benefits, tax consequences, and financing. It also addresses the combined company's future plans, objectives, expectations, and intentions, while cautioning that actual results may differ materially due to various risks and uncertainties.

Management Comments

• Communications regarding the proposed business combination were made available by Thomas Polen, Chairman, Chief Executive Officer and President of Becton, Dickinson and Company, on LinkedIn and X.

Industry Context

This filing pertains to a specific business combination within the healthcare and life sciences sectors, involving a spin-off of BD's biosciences and diagnostic solutions business and its merger with Waters Corporation. The document focuses on the transactional and regulatory aspects rather than broader industry trends, though it acknowledges general economic and industry-specific conditions as potential risk factors.

Comparison to Industry Standards

• The document does not provide specific financial results or operational data that would allow for a direct comparison to industry standards or benchmarks.
• It is a procedural filing related to a proposed transaction, focusing on forward-looking statements and associated risks rather than performance metrics of comparable companies or projects.

Legal Proceedings

• Risk of stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations.
• Such litigation may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Potential impact on shareholders of Waters and BD, who are urged to review forthcoming proxy and information statements.
• Potential disruption of management time from ongoing business operations due to the pendency of the proposed transaction.
• Potential effects of the pendency of the proposed transaction on the relationship of any of the parties with their employees.
• Potential effects of the pendency of the proposed transaction on the relationship of any of the parties with their customers.
• Potential effects of the pendency of the proposed transaction on the relationship of any of the parties with their suppliers.
• Potential effects of the pendency of the proposed transaction on the relationship of any of the parties with other counterparties.

Next Steps

• Waters and BD intend to file relevant materials with the SEC, including a registration statement on Form S-4 by Waters.
• The Form S-4 will include a preliminary and definitive proxy statement/prospectus of Waters, which will be mailed to Waters stockholders.
• SpinCo intends to file a registration statement on Form 10, which will serve as an information statement/prospectus in connection with the spin-off of SpinCo from BD.
• Investors and security holders are urged to read the proxy statement/prospectus, the information statement/prospectus, and any other documents that will be filed with the SEC, as well as any amendments or supplements to these documents, carefully and in their entirety when they become available.
• Changes in holdings of Waters and BD securities by their directors or executive officers will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC.

Key Dates

Keywords

Becton Dickinson, BD, Waters Corporation, Waters, Augusta SpinCo Corporation, SpinCo, Merger, Acquisition, Spin-off, Biosciences, Diagnostic Solutions, SEC Filing, Form 425, Corporate Transaction, Healthcare, Life Sciences